https://jbmtct.com.br/seer/index.php/jbmtct/issue/feedJOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY2024-09-02T16:05:26+00:00Fernando Barroso Duartejournalbmtct@sbtmo.org.brOpen Journal Systems<p>The JBMTCT is an official electronic scientific publication of the Brazilian Society of Bone Marrow Transplantation (SBTMO), created in 2020, edited every three months and in compliance with a defined editorial policy.</p> <p>Publishes letter to the editor, unpublished articles, review articles, short communication, opinion articles, case reports, conduct protocols and research articles in progress / completed with the aim of spreading knowledge and innovative research in medicine fields, bone marrow transplantation, cell therapy and related sciences.</p> <p>Target audience: this journal is aimed to researchers, teachers, professionals and students with an interest in the medicine field (bone marrow transplantation and cell therapy) and related sciences.<br /><br />Periodicity of the jornal:<br />Quarterly</p>https://jbmtct.com.br/seer/index.php/jbmtct/article/view/237Commentary article on AI and EI2024-07-22T13:41:43+00:00Hans-Jochem Kolbh-j-kolb@web.de2024-07-24T00:00:00+00:00Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPYhttps://jbmtct.com.br/seer/index.php/jbmtct/article/view/244HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR ALL: A report from the 2024 Congress of the Brazilian Bone Marrow Transplantation and Cellular Therapy Society (SBTMO) 2024-09-02T16:05:26+00:00Fernando Barroso Duartenutriquimo@uol.com.brKarine Sampaio Nunes Barrosokarinesampaionb@gmail.comLuiz Guilherme Darrigo Junirodarrigo.jr@gmail.comCarmem Maria Sales Bonfimcarmembonfim@gmail.com<p>This article analyzes current data, and the main challenges faced in Hematopoietic cell Transplantation (HCT) in Brazil, as presented at the SBTMO 2024 meeting, with the aim of guiding future actions. Topics discussed included the waiting list for HCT transplants, access to beds for adults and pediatric patients, and the need for a more efficient distribution of resources across the country. Among the identified needs were the creation of a program to expand access to transplants through the Brazilian Unified Health System (SUS), the importance of health registries for data-driven decisions, and the development of the <em>"Mais Saúde Amazônia"</em> project to expand transplant centers in the Amazon region. Additionally, the provision of financial incentives for transplant centers, the implementation of mentorship programs to increase access to HCT, and the formation of a cooperative network between SBTMO (Brazilian Society of Bone Marrow Transplantation and Cellular Therapy), ABHH (Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy), ANVISA (Brazilian Health Regulatory Agency), ABRALE (Brazilian Association of Lymphoma and Leukemia), and INCA (Brazilian National Cancer Institute) to improve the integration of HCT services were discussed</p>2024-09-25T00:00:00+00:00Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPYhttps://jbmtct.com.br/seer/index.php/jbmtct/article/view/235EMERGING ACTIVITY OF CELLULAR IMMUNOTHERAPY FOR TREATMENT OF CANCER IN BRAZIL2024-07-05T11:40:03+00:00Cinthya Corrêa da Silvacinthya.silva@einstein.brAnderson João Simioneajsimione@hotmail.comPaula Moreira da Silva Sabainipauladc@gmail.comAntonio Vaz Macedoantoniovmac@gmail.comHeliz Regina Alves das Nevesheliz.neves@hc.ufpr.brMonique Ammi mammi@NMDP.ORGFlavia Ferreira da Costaflaviafdacosta@gmail.comValeria Vianavaleriavianna.ufrj@gamil.comAdriana Mendes de Quadros Cavilhaadriana.cavilha@hc.ufpr.brRosana Rocha Conciliorosana.concilio@bp.org.brPhillip Scheinbergscheinbp@bp.org.brNelson Hamerschlakhamer@einstein.brMarco Aurelio Salvinomarcohemato@hotmail.comAdriana Seber adrianaseber@gmail.comYana Augusta Sarkis Novisyananovis@yahoo.comVanderson Geraldo Rochavanderson.rocha@hc.fm.usp.brJoaquim Gasparini dos Santosjoaquimgasparini@gmail.comLucia Mariano da Rocha Silladralucia.silla@gmail.comRicardo Chiattonericardo.chiattone@gmail.comAndreza Alice Feitosa Ribeiroandreza.ribeiro@einstein.brVaneuza Araújo Moreira Funkevfunke@gmail.comLeonardo Javier Arcurileonardo.arcuri@einstein.brLucila Nassif kerbauylucila.kerbauy@einstein.brJayr Schmidt Filhojayrsf@gmail.comCarmem Maria Sales Bonfimcarmem.bonfim@gmail.comSimone Ojima Ferreirasimone.ojima@gmail.comMarcelo Pasquinimpasquini@mcw.eduFernando Barroso Duartenutriquimio@uol.com.br<p>Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved for standard of care treatment of patients with lymphoma and leukemia worldwide. Here we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 38 patients who received CAR T cells between 2020 and 2023. The median age was 47 years (range 4-77). Indications include Non-Hodgkin Lymphoma (NHL; 26 cases; 68%), Acute Lymphoblastic Leukemia (ALL; 9 cases; 24%), and Multiple Myeloma (MM; 3 cases; 8%). 84% (75% - 24 NHL cases and 25% - 8 ALL cases) were commercial. This report demonstrates the initial implementation of CAR T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements. </p>2024-07-24T00:00:00+00:00Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY